NCT02095665View on ClinicalTrials.gov

Ureteral Stent-related Pain and Mirabegron (SPAM) Trial

PHASE4CompletedINTERVENTIONAL
Enrollment

22

Participants

Timeline

Start Date

January 1, 2014

Primary Completion Date

March 23, 2018

Study Completion Date

March 23, 2018

Conditions
Nephrolithiasis
Interventions
DRUG

Mirabegron

50 mg of Mirabegron daily from stent insertion until removal 5 to 10 days

DRUG

Tamsulosin

0.4 mg of Tamsulosin daily and 1 tab of Percocet every 4 hours as necessary from stent insertion until removal 5 to 10 days

DRUG

Tylenol #3

1 tab of Tylenol #3 every 6 hours as necessary from stent insertion until removal 5 to 10 days

Trial Locations (1)

B3H 2Y9

Nova Scotia Health Authority, Central, Halifax

All Listed Sponsors
lead

Nova Scotia Health Authority

OTHER

NCT02095665 - Ureteral Stent-related Pain and Mirabegron (SPAM) Trial | Biotech Hunter | Biotech Hunter